Monoclonal antibodies in the treatment of ovarian cancer

European Journal of Gynaecological Oncology

Volumn 24, Issue 1, 2003, Pages 7-11

  Markowska, J ^a,b  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b Dept of Gynecology   (Poland)

Author keywords

Monoclonal antibodies; Ovarian cancer

Indexed keywords

ALEMTUZUMAB; BEVACIZUMAB; BREVAREX; CA 125 ANTIGEN; GEMTUZUMAB OZOGAMICIN; GROWTH FACTOR; IBRITUMOMAB TIUXETAN; IMMUNOTOXIN; INTERLEUKIN 12; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY HMFG1; MONOCLONAL ANTIBODY MN 14; OREGOVOMAB; OZOGAMICIN; PACLITAXEL; PEMTUMOMAB; RITUXIMAB; TIUXETAN; TRASTUZUMAB; UNCLASSIFIED DRUG;

BONE MARROW TOXICITY; CANCER RECURRENCE; CANCER REGRESSION; CHIMERA; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; FEVER; FLU LIKE SYNDROME; HUMAN; LIVER TOXICITY; NAUSEA; NEUROTOXICITY; OVARY CANCER; REVIEW; VOMITING;

ANTIBODIES, MONOCLONAL; CARCINOMA; CLINICAL TRIALS; FEMALE; HUMANS; IMMUNOTHERAPY; OVARIAN NEOPLASMS; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0037287831     PISSN: 03922936     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. Köhler G., Milstein C.: "Continuous cultures of fused cells secreting antibody of predefined specifity". Nature, 1975, 495.
2. Bast R. C. Jr., Klug T. L., St-John E., Jenison E., Niloff J. M., Lazarus H. et al.: "A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer". N. Engl. J. Med., 1983, 13, 309 (15), 883.
3. Nicodemus Ch. F., Schultes B. C., Hamilton B. L.: "Immunomodulation with antibodies: clinical application in ovarian cancer and other malignancies". Expert. Rev. Vaccines, 2002, 1, 35.
4. Wiseman G. A., White C. A., Stabin M., Dunn W. L. et al.: "Phase I/II 90Y Zevalin TM/90 yttrium ibritumomab tiuxetan. IDEC-42B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma". Eur. J. Nucl. Med., 2000, 27 (2), 766.
5. Hamann P. R., Hinman L. H., Hollander J. et al.: "Gemtuzumab ozogamicin, a potent and selective anti CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia". Bioaconjug. Chem., 2002, 13 (1), 47.
6. Yip Y. L., Ward R.: "AntiErb B-2 monoclonal antibodies and Erb B-2 directed vaccines". Cancer Immunol. Immunother., 2002, 50, 11, 569.
7. Epenetos A. A., Hooker G., Krausz T., Snook D., Bodmer W. F.: "Antibody-guided irradiation of malignant ascites in ovarian cancer: a new therapeutic method possessing specificity against cancer cells". Obstet. Gynecol., 1986, 68 (suppl. 3), 71S.
8. Courtenay-Luck N. S., Epenetos A. A., Sivolapenko G. B., Larche M., Barkans J. R., Ritter M. A.: "Development of anti-idiotypic antibodies against tumour antigens and autoantigens in ovarian cancer patients treated intraperitoneally with mouse monoclonal antibodies". Lancet, 1988, 15, 2 (8616), 894.
9. Finkler N. J., Muto M. G., Kassis A. I., Weadock K., Tumeh S. S., Zurawski V. R. Jr, Knapp R. C.: "Intraperitoneal radiolabeled OC 125 in patients with advanced ovarian cancer". Gynecol. Oncol., 1989, 34 (3), 339.
10. Juweid M., Sharkey R. M., Alavi A., Swayne L. C., Herskovic T., Hanley D. et al.: "Regression of advanced refractory ovarian cancer treated with iodine-131-labeled anti-CEA monoclonal antibody". J. Nucl. Med., 1997, 38 (2), 257.
11. Schmolling J., Reinsberg J., Wagner U., Krebs D.: "Anti-TAG-72 antibody B72.3-immunological and clinical effects in ovarian carcinoma". Hybridonia, 1997, 16 (1), 53.
12. Muto M. G., Finkler N. J., Kassis A. I., Howes A. E., Anderson L. L., Lau C. C. et al.: "Intraperitoneal radioimmunotherapy of refractory ovarian carcinoma utilizing iodine-131-labeled monoclonal antibody OC 125". Gynecol. Oncol., 1992, 45 (3), 265.
13. Griffin T. W., Collins J., Bokhari F., Stochl M., Brill A. B., Ito T, et al.: "Intraperitoneal immunoconjugates". Cancer Res., 1990, 1, 50 (suppl. 3), 1031s.
14. Sweet F., Rosik L. O., Sommers G. M., Collins J. L.: "Daunorubicin conjugated to a monoclonal anti-CA125 antibody selectively kills human ovarian cancer cells". Gynecol. Oncol., 1989, 34 (3), 305.
15. nd, Longo D. L. et al.: "Clinical evaluation of intraperitoneal Pseudomonas exotoxin immunoconjugate OVB3-PE in patients with ovarian cancer". J. Clin. Oncol., 1991, 9 (12), 2095.
16. Apelgren L. D., Zimmerman D. L., Briggs S. L., Bumol T. F.: "Antitumor activity of the monoclonal antibody - Vinca alkaloid immunoconjugate LY203725 (KS 1/4-4- desacetylvinblastine-3-carboxhydrazine) in a nude mouse model of human ovarian cancer". Cancer Res., 1990, 15, 50 (12), 3540.
17. Beck E., Hofmann M., Bernhardt G., Jager W., Wildt L., Lang N.: "In vitro activity of immunoconjugates between cisplatin and an anti-CA 125 monoclonal antibody on ovarian cancer cell lines". Cell Biophys., 1994, 24, 25163.
18. Jaime J., Page M.: "Paclitaxel immunoconjugate for the specific treatment of ovarian cancer in vitro". Anticancer Res., 2001, 21 (2A), 1119.
19. Kosmas C., Epenetos A. A., Courtenay-Luck N. S.: "Activation of cellular immunity after intracavitary monoclonal antibody therapy of ovarian cancer". Cancer, 1994, 15, 73 (12), 3000.
20. Baum R. P., Niesen A., Hertel A., Nancy A., Hess H., Donnerstag B. et al.: "Activating anti-idiotypic human anti-mouse antibodies for immunotherapy of ovarian carcinoma". Cancer, 1994, 1, 73 (suppl. 3), 1121.
21. Schmolling J., Reinsberg J., Wagner U., Krebs D.: "Antiidiotypic antibodies in ovarian cancer patients treated with the monoclonal antibody B72.3". Hybridoma, 1995, 14 (2), 183.
22. Reinartz S., Boerner H., Koehler S., Von Ruecker A., Schlebusch H., Wagner U.: "Evaluation of immunological responses in patients with ovarian cancer treated with the anti-idiotype vaccine ACA125 by determination of intracellular cytokines - a preliminary report". Hybridoma, 1999, 18 (1), 41.
23. Muto M. G., Finkler N. J., Kassis A. I., Lepisto E. M., Knapp R. C.: "Human anti-murine antibody responses in ovarian cancer patients undergoing radioimmunotherapy with the murine monoclonal antibody OC-125". Gynecol. Oncol., 1990, 38 (2), 244.
24. Stewart J. S., Hird V., Snook D., Dhokia B., Sivolapenko G., Hooker G. et al.: "Intraperitoneal yttrium-90-labeled monoclonal antibody in ovarian cancer". J. Clin. Oncol., 1990, 8 (12), 1941.
25. Crowther M. E., Ward B. G., Granowska M., Mather S., Britton K. E., Shepherd J. H., Slevin M. L.: "Therapeutic considerationis in the use of intraeritoneal radiolabelled monoclonal antibodies in ovarian carcinoma". Nucl. Med. Commun., 1989, 10 (3), 149.
26. Bolhuis R. L., Lamers C. H., Goey S. H., Eggermont A. M., Trimbos J. B., Stoter G. et al.: "Adoptive immunotherapy of ovarian carcinoma with bs-Mab-targeted lymphocytes: a multicenter study". Int. J. Cancer Suppl., 1992, 7, 78.
27. Muto M. G., Finkler N. J., Kassis A. I., Lepisto E. M., Knapp R. C.: "Human anti-murine antibody responses in ovarian cancer patients undergoing radioimmunotherapy with the murine monoclonal antibody OC-125". Gynecol. Oncol., 1990, 38 (2), 244.
28. Miotti S., Negri D. R., Valota O., Calabrese M., Bolhuis R. L., Gratama J. W. et al.: "Level of anti-mouse-antibody response induced by bi-specific monoclonal antibody OC/TR in ovarian carcinoma patients in associated with longer survival". Int. J. Cancer, 1999, 19, 84 (1), 62.
29. Schultes Ph. D.: "Oral presentation 19th International Advances in the Application of Monoclonal Antibodies in Clinical Oncology" Conference, June 26-28 2002, Vouliagmenti, Greece.
30. Gordon A.: "20 patient, -chemo-immunotherapy" study of OvaRex®". The annual meeting of the Society of Gynecologic Oncologists (SGO), March 16-20, 2002 in Miami.
31. Hird V., Maraveyas A., Snook D., Dhokia B., Soutter W. P., Meares C. et al.: "Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody". Br. J. Cancer, 1993, 68 (2), 403.